FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
Tweet Send to a Friend
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE (daraxonrasib), a once-daily oral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


